Secondary outcomes were change in liver histology ( 12 control and 16 ezetimibe patients ) , insulin sensitivity including a hyperinsulinaemic-euglycaemic clamp study ( ten control and 13 ezetimibe patients ) and hepatic fatty acid composition ( six control and nine ezetimibe patients ) .